Buprenorphine and postpartum contraception utilization among people with opioid use disorder: a multi-state analysis

Table 2 Adjusted analyses for contraception receipt 90 days after delivery

			Adjusted risk ratio [95% confidence intervals]
Model 1		Any contraception vs. no contraception	1.17 [1.07–1.28]
Model 2 Differentiating between highly-effective and effective subtypes	Highly-effective	LARC vs. no contraception	1.00 [0.95–1.04]
	Highly-effective	Female sterilization vs. no contraception	1.01 [0.98–1.06]
	Effective	Injection, OCP, patch, or ring vs. no contraception	1.09 [1.04–1.13]
Model 3 Differentiating between prescribed and provider-administered subtypes	Provider-administered	LARC vs. no contraception	1.00 [0.95–1.04]
	Provider-administered	Female sterilization vs. no contraception	1.01 [0.98–1.06]
	Provider-administered	Injection vs. no contraception	0.95 [0.91–0.99]
	Prescribed	OCP, patch, or ring vs. no contraception	1.13 [1.08–1.18]

Models above are controlling for age (< 30 vs. = > 30), race, (non-Hispanic Black vs. Hispanic vs. other vs. non-Hispanic White), and co-occurring disorders (alcohol/ stimulant /sedative use disorder; anxiety disorder; mood disorder; insomnia; migraine chronic pain). Full models can be found in the Supplementary Information

ISSN: 1940-0640